ADTX
Aditxt, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+7.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.3K | 3.2K | 134.0K | 645.2K | 933.7K |
| Cost of Revenue | 11.5K | 2.9K | 627.5K | 756.8K | 766.8K |
| Gross Profit | 2.9K | 268.00 | (493.0K) | (111.7K) | 166.9K |
| Operating Expenses | |||||
| R&D Expense | 3.0M | 3.2M | 10.9M | 7.1M | 7.3M |
| SG&A Expense | 15.3M | 16.4M | 16.5M | 18.9M | 17.8M |
| General & Admin Expense | 14.9M | 16.0M | 16.3M | 18.6M | 16.0M |
| Selling & Marketing Expense | 351.1K | 402.0K | 197.9K | 269.3K | 1.8M |
| Other Expenses | — | — | — | — | 544.0K |
| Total Operating Expenses | 18.3M | 19.6M | 27.4M | 26.0M | 25.6M |
| Cost and Expenses | 18.3M | 19.6M | 28.0M | 26.7M | 26.4M |
| Operating Income (EBIT) | (18.3M) | (19.6M) | (27.9M) | (26.1M) | (25.5M) |
| Non-Operating | |||||
| Interest Income | 200.2K | 200.2K | 1.5K | 10.2K | 57.3K |
| Interest Expense | 2.1M | 2.4M | 7.4M | 6.4M | 2.3M |
| Net Interest Income | (1.8M) | (2.2M) | (7.4M) | (6.4M) | (2.2M) |
| Other Non-Op Income/Expense | (34.7M) | (23.2M) | (7.2M) | (6.3M) | (2.2M) |
| Non-Operating Income (excl Interest) | 32.6M | 20.8M | (207.0K) | (61.9K) | (116.0K) |
| EBT (Pre-Tax Income) | (53.0M) | (42.8M) | (35.0M) | (32.4M) | (27.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (52.0M) | (41.7M) | (34.4M) | (32.4M) | (27.6M) |
| Earnings from Cont. Ops | (53.0M) | (42.8M) | (35.0M) | (32.4M) | (27.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (53.3M) | (43.1M) | (40.4M) | (32.7M) | (27.6M) |
| Per Share | |||||
| Basic EPS | ($1,490.72) | ($1,153.83) | ($3,062.42) | $0.00 | $0.00 |
| Diluted EPS | ($1,490.72) | ($1,153.83) | ($3,062.42) | $0.00 | $0.00 |
| Revenue Per Share | $0.71 | $0.09 | $11.91 | — | — |
| Shares | |||||
| Basic Shares Outstanding | 20174 | 37355 | 11248 | — | — |
| Diluted Shares Outstanding | 20174 | 37355 | 13177 | — | — |
| Profitability Metrics | |||||
| EBITDA | (50.7M) | (40.1M) | (27.0M) | (25.5M) | (24.8M) |
| D&A | 252.0K | 272.6K | 617.3K | 542.6K | 536.0K |
| EBIT | (50.9M) | (40.4M) | (27.7M) | (26.0M) | (25.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026